Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
5.130
+0.220 (+4.48%)
Streaming Delayed Price
Updated: 11:49 AM EDT, Apr 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
January 12, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Myriad Genetics, Inc.
Via
GlobeNewswire
3 Stocks Under $10 We Think Twice About
January 04, 2026
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as...
Via
StockStory
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
3 Unprofitable Stocks That Fall Short
January 01, 2026
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
Via
StockStory
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
December 22, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 3.7% in the afternoon session after the company signed an exclusive agreement with Zydus Lifesciences to commercialize a trio of...
Via
StockStory
Why Myriad Genetics (MYGN) Stock Is Up Today
December 09, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 2.5% in the afternoon session after the company announced it would present new data from eight studies at the 2025 San Antonio...
Via
StockStory
Topics
Artificial Intelligence
Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium
December 09, 2025
New data will be presented about Precise® Molecular Residual Disease (MRD) Test and MyRisk® Hereditary Cancer Test
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings?
December 08, 2025
Myriad Genetics’s 38.9% return over the past six months has outpaced the S&P 500 by 24.6%, and its stock price has climbed to $7.21 per share. This was partly due to its solid quarterly results, and...
Via
StockStory
Topics
Stocks
1 Healthcare Stock with Promising Prospects and 2 We Question
December 02, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized strong financial performance, and over the past...
Via
StockStory
Topics
Economy
Stocks
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today
December 01, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6% in the afternoon session after the U.S. Food and Drug Administration (FDA) approved a competing blood-based test for prostate...
Via
StockStory
Topics
Government
Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health
November 25, 2025
Actionable offering helps enable earlier, more personalized breast cancer interventions
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To Know
November 24, 2025
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government...
Via
StockStory
Topics
Economy
Government
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know
November 21, 2025
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated...
Via
StockStory
Topics
Economy
Why Myriad Genetics (MYGN) Stock Is Up Today
November 19, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 0.4% in the afternoon session after the company shared a positive outlook, projecting significant revenue from its hereditary...
Via
StockStory
Topics
Artificial Intelligence
Stocks
Q3 Earnings Roundup: Myriad Genetics (NASDAQ:MYGN) And The Rest Of The Therapeutics Segment
November 18, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.
Via
StockStory
Topics
Artificial Intelligence
1 High-Flying Stock with Solid Fundamentals and 2 We Question
November 13, 2025
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,...
Via
StockStory
Topics
Artificial Intelligence
Economy
Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know
November 11, 2025
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...
Via
StockStory
Topics
Artificial Intelligence
Stocks
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
November 11, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
November 10, 2025
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test
From
Myriad Genetics, Inc.
Via
GlobeNewswire
The Top 5 Analyst Questions From Myriad Genetics’s Q3 Earnings Call
November 10, 2025
Myriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted negatively due to ongoing challenges in average revenue per test and...
Via
StockStory
Topics
Earnings
Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
November 06, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 04, 2025
Via
Benzinga
Why Myriad Genetics (MYGN) Stock Is Down Today
November 04, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 19.3% in the morning session after it reported mixed third-quarter results that were overshadowed by a weak earnings outlook.
Via
StockStory
Topics
Economy
Government
World Trade
MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds
November 04, 2025
Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year...
Via
StockStory
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops
November 03, 2025
Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year...
Via
StockStory
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
November 03, 2025
From
Myriad Genetics, Inc.
Via
GlobeNewswire
What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings
November 01, 2025
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect.
Via
StockStory
Exploring Myriad Genetics's Earnings Expectations
↗
October 31, 2025
Via
Benzinga
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
October 31, 2025
Faster initial remission and response, persistent benefit over six months
From
Myriad Genetics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
